Wendy future of retail top

Novo Nordisk releases Saxenda weight-control pen in U.S.

Print Friendly, PDF & Email

PLAINSBORO, N.J. — Novo Nordisk Inc. has launched Saxenda, a weight-control drug delivered via an injector pen, in the United States.

Novo Nordisk Inc SaxendaThe company said Wednesday that Saxenda (liraglutide injection) is the first, once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management in adults.

Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (body mass index greater than or equal to 30 kg/m2) or who are overweight (BMI greater than or equal to 27 kg/m2) in the presence of at least one weight-related comorbid condition.

“Novo Nordisk is pleased to offer a new treatment that can provide some patients who have obesity or are overweight with comorbidities a new path to achieving clinically meaningful weight loss,” stated Jesper Hoiland, president of Novo Nordisk. “We believe the launch of Saxenda represents a significant contribution to the therapeutic options that are advancing obesity care. For Novo Nordisk, it also aligns with our long-term commitment to help patients with chronic disease.”

Obesity has recently been recognized as a disease by the American Medical Association and other medical societies as the prevalence of the condition has grown in the United States and across the globe, Novo Nordisk noted. The company reported that approximately 35% of the U.S. adult population lived with obesity in 2011 to 2012.

Saxenda was evaluated in the SCALE (Satiety and Clinical Adiposity-Liraglutide Evidence in Nondiabetic and Diabetic people) phase three clinical program, which involved more than 5,000 study participants who are obese or overweight, with weight-related comorbidities. Trial data showed that the drug, in combination with a reduced-calorie diet and increased physical activity, resulted in significantly greater weight loss in some patients than reduced-calorie diet and physical activity alone.

“Diet and increased physical activity are important and should be part of any weight-loss program. However, for some people with obesity, a pharmacotherapy treatment option like Saxenda may be needed to help them with chronic weight management,” commented SCALE clinical trial investigator Dr. Ken Fujioka of the Department of Nutrition and Metabolic Research at Scripps Clinic in La Jolla, Calif.


ECRM_06-01-22


Comments are closed.

PP_1170x120_10-25-21